4-甲胺基-6-三氟甲基-2-甲砜基嘧啶的合成及其晶体结构

以三氟乙酰乙酸乙酯和硫脲为原料,经环化、氯化和亲核取代反应制得中间体4-甲胺基-6-三氟甲基-2-甲硫基嘧啶(3); 以间氯过氧苯甲酸为氧化剂,3经氧化反应合成了新化合物--4-甲胺基-6-三氟甲基-2-甲砜基嘧啶(4),其结构经¹H NMR,MS,元素分析和X-射线单晶衍射表征。 4（CCDC：973037）属单斜晶系,空间群:P₂(1)/c,晶胞参数a=5.068 7(4) , b=15.296 8(11) , c=13.833 9(10) , β=13.833 9(10)°, V=1 065.81(14) ³, Z=4, Dc＝1.591 g·cm-³, μ=0.336 mm^-1, F(000)=520, R₁=0.051 1, wR₂=0.135 3。     

偕双硅高烯丙胺的硅基aza-Prins环化反应研究

在三氟甲磺酸三甲基硅酯作用下,偕双硅高烯丙胺与醛发生硅基aza Prins环化反应,合成了9个C4位含环外烯基硅的新型哌啶类化合物,收率47%~96%,其结构经¹H NMR, ¹³C NMR和LC-MS（ESI）表征,Z/E比由产物的¹H NMR分析得到;主要异构体的环外烯基硅构型经¹H, ¹H COSY和NOE确证。醛上取代基的电子效应对所生成的烯基硅的构型有较大影响：芳环取代对应Z-式构型,拉电子酯基取代对应单一的E-式构型产物。     

硫代靛红衍生的三氟乙基酮亚胺的合成

以硫代靛红和三氟乙胺盐酸盐为原料,以原甲酸三甲酯为脱水剂,在温和条件下以5%～35%收率合成了11个新型的硫代靛红衍生的三氟乙基酮亚胺衍生物3a～3k,其结构经¹H NMR、¹³C NMR和HR-MS(ESI-TOF)表征。初步尝试了该亚胺和苯并噻吩砜的[3+2]环加成反应,得到了含三氟甲基的多环杂环化合物。     

新型15-N-取代苦参碱亚胺衍生物的合成及其抗肿瘤活性

以苦参碱为起始原料，二氯甲烷为溶剂，经三氯氧磷催化与9种芳胺反应合成了一系列新型15-N-取代苦参碱亚胺衍生物(3a~3i)，其结构经¹H NMR， ¹³C NMR 和MS(ESI)表征。采用X-射线单晶衍射仪测定了化合物3a的绝对构型。体外活性测试结果表明：3d和3f对人肝癌细胞HepG2和人宫颈癌细胞HeLa的半数抑制率显著优于苦参碱。     

新型1-取代-3-(4-甲氧基苯基)脲衍生物的合成及其生物活性

以对甲氧基苯胺和固体三光气为起始原料,制得4-甲氧基苯异氰酸酯（1）; 1与取代胺（2a~2i）反应合成了9个新型的1-取代-3-(4-甲氧基苯基)脲衍生物（3a~3i）,其结构经¹H NMR, ¹³C NMR和HR-MS表征。用黄瓜子叶扩张法和小麦芽鞘法研究了3a~3i的生物活性。结果表明：1-（4-甲氧基苯基)-3-［3-（三氟甲基)苯基］脲(3c)的生长素活性最好。在用药浓度为10 mg·L^-1时,3c的生长素活性为29.8%,优于β-吲哚乙酸（29.3%）。     

苯并噻吩衍生的三氟乙基酮亚胺的合成

鉴于含氟化合物在药物化学领域起到愈发重要的作用,以苯并噻吩酮和三氟乙胺为原料,在四氯化钛脱水作用下,合成9个新型苯并噻吩衍生的三氟乙基酮亚胺衍生物(3a～3i)。同时,初步尝试了三氟乙基苯并噻吩酮亚胺和2-硝基苯并呋喃的[3+2]去芳构化环加成反应,得到了含三氟甲基的多环杂环化合物(5)。最后对这些化合物的结构进行了¹H NMR、¹³C NMR和HR-MS(ESI-TOF)表征。     

(S)-2,2,2-三氟-1-(2-甲基-1H-1-吲哚基)乙胺的不对称合成

以2-甲基吲哚为原料,在碱性条件下与α-三氟甲基醛亚胺经加成反应合成了关键中间体——含三氟甲基的(S)-叔丁基亚磺酰胺(3),收率95%,d/r99/1;3脱除保护基得(S)-2,2,2-三氟-1-(2-甲基-1H-1-吲哚基)乙胺(4),收率97%,其结构经1H NMR,13C NMR,19F NMR,FT-IR,EI-MS和HR-EI-MS确证。     

新型螺[氧化吲哚-3,3′-吡唑]-5′-二氟甲基-4′-甲酸酯类化合物的合成

以原位生成的二氟甲基重氮甲烷（CF₂HCHN₂）与靛红衍生的3-烯基氧化吲哚为原料,通过[3+2]环加成反应和1,3-H迁移过程,合成了3种结构新型的螺[氧化吲哚 3,3′-吡唑]-5′-二氟甲基-4′-甲酸酯类化合物,收率41~68%, dr 91: 9~99 : 1,其结构经¹H NMR, ¹³C NMR, ¹⁹F NMR和HR-MS(ESI-TOF)表征。并通过单晶X-射线单晶衍射确定其相对构型。     

新型异噁唑-三氟甲基螺环氧化吲哚类化合物的合成及其抗白血病活性

以硝基异噁唑苯乙烯与靛红衍生的三氟甲基亚胺为原料,在有机碱三乙胺的催化作用下,发生Michael加成环化反应,得到了12个未见文献报道的异噁唑-三氟甲基螺环氧化吲哚类化合物3a~3l,产率73%~89%,dr值10/1~>20/1, 其结构经¹H NMR, ¹³C NMR和HR-MS（ESI-TOF）表征,通过单晶进一步进行了确定化合物3e的相对构型。该类化合物含有连续4个立体中心,其中包含一个螺环季碳中心。采用MTT法研究了3a~3l对人白血病细胞(K562)的体外抗肿瘤活性。结果表明：化合物3c,3d,3h和3i对K562具有一定的抑制活性, 说明异噁唑-三氟甲基螺环氧化吲哚骨架可以作为抗肿瘤先导化合物进一步研究。     

不对称催化合成2-[[3-{[3-氯-5-(三氟甲基)吡啶-2-基]-氧基}苯氧基](苯基)甲基]丙烯酸甲酯

以苯甲醛、丙烯酸甲酯、2,3-二氯-5-三氟甲基吡啶和间苯二酚为原料,分别合成了MBH乙酸酯（6）和取代苯酚（9）;在(DHQD)₂PHAL催化下,6和9经不对称反应立体选择性合成了2-【【3-{[3-氯-5-(三氟甲基)吡啶-2-基]-氧基}苯氧基】(苯基)甲基】丙烯酸甲酯,产率50%, ee 94%,其结构经¹H NMR, ¹³C NMR和HR-MS确证。     

Total synthesis and stereochemistry of pinnatoxins B and C

[Structure: see text] Pinnatoxins B and C were synthesized from diols (34R)-3b and (34S)-3a, respectively, in a stereochemically controlled manner. Through extensive analysis of the 1H NMR spectra of synthetic PnTXs B and C, the diagnostic NMR signals were first identified to differentiate (34S)- and (34R)-diastereomers and then used to establish the C34 configuration of natural PnTXs B and C as 34S and 34R, respectively.     

盐酸普拉克索的合成工艺改进

以(S)-2,6-二氨基-4,5,6,7-四氢苯并噻唑（3）为原料,经缩合、还原反应制得普拉克索（2）; 2与盐酸成盐后制得盐酸普拉克索一水合物（1）,其结构经¹H NMR, ¹³C NMR, IR和MS（ESI）确证。研究了溶剂、反应温度、投料比γ［n(3) : n(正丙醛)］、析晶终止温度和精制降温速度对1收率的影响。结果表明：在最佳反应条件（无水甲醇为溶剂,γ=1.0 : 1.8,于-15~-20 ℃反应,析晶终止温度为-5~-10 ℃）下,最高收率可达61.5%。     

Total synthesis and absolute configuration of minalemine A, a guanidine peptide from the marine tunicate Didemnum rodriguesi

The total synthesis of the 3S,2S and 3R,2S diastereomers (1a and 1b) of minalemine A and the identification of the natural compound as the 3R,2S isomer is described. The key step in the synthesis is the preparation of the two enantiomers of the beta-amino diacid 3-(N-carboxymethyl)-aminodecanoic acid (Ncma), which were obtained by stereoselective alkylation with allyl bromide of two nonanoic acid imides bearing chiral oxazolidinones as chiral auxiliaries. Natural minalemine A shows identical 1H NMR and very similar 13C NMR spectra compared to the two synthetic diastereomers. Sufficient differences in their chromatographic behavior to allow conclusive identification were not found. However, the corresponding N-2-naphthoyl amides presented quite distinct circular dichroism spectra (CD), and these confirmed the 3R,2S configuration for the natural minalemines and the R configuration for the constituent beta-amino diacid, Ncma.     

NMR spectroscopic analysis of new spiro-piperidylrifamycins

New spiro-piperidylrifamycin derivatives are presented. These compounds were synthesized from the reaction of 3-amino-4-iminorifamycin S and enantiomerically pure 4-piperidones, which generate diasteroisomeric rifabutin analogues with a new stereocentre at the spiranic carbon. The (1)H and (13)C NMR spectra of these new compounds, and also the configuration of the new stereogenic centres, were assigned using 2D NMR spectroscopic techniques. A preliminary study of the (1)H and (13)C NMR spectra of the starting compounds rifamycin S, 3-amino-4-iminorifamycin S and the related rifabutin was also carried out and as a result, their previously published (13)C NMR data were corrected.     

Tris(pyronato)- and tris(pyridonato)-ruthenium(III) complexes and solution NMR studies

The water-soluble Ru(III) maltolato, ethylmaltolato, and pyridonato complexes, Ru(O-O')3 (O-O' = ma (1a), etma (1b), pyd (2a)), were synthesized (Hma = 3-hydroxy-2-methyl-4-pyrone, Hetma = 2-ethyl-3-hydroxy-4-pyrone, Hpyd = 3-hydroxy-1,2-dimethyl-4-pyridone). The complexes were characterized by elemental analysis, NMR and IR spectroscopies, MS, solution conductivity, and cyclic voltammetry, and in the case of Ru(ma)(3), by X-ray crystallography, which revealed a mer configuration. The paramagnetic 1H NMR resonances of 1a, 1b, and 2a were assigned using 2D methods (1H COSY and 1H-13C HMQC) and variable-temperature 1H NMR data and showed that 1a and 1b exist in aqueous solution predominantly as a mer isomer, while 2a is a mixture of mer and fac isomers. Although a 13C NMR spectrum could not be measured directly for 1a, a partial (13)C spectrum was generated from the 1H-13C HMQC spectrum. Complexes 1a and 1b were tested for anti-proliferatory activity against the human breast cancer cell line MDA-MB-435S and gave IC50 values of 140 and 90 microM, respectively.     

膜荚黄芪苷元的结构

从膜荚黄芪的根中分得膜荚黄芪皂苷甲,皂苷乙和皂苷丙.膜荚黄芪皂苷甲是主要成分.药理试验有降压和抗炎作用、皂苷甲经Smith氧化降解得到膜荚黄芪苷元1.用IR,~1HNMR,~(13)C NMR,MS和化学降解证明其结构为1.根据镧系位移试剂的~1H NMR,1的C_(20)和C_(24)的构型分别确定为S和R.     

抗丙肝药物维拉帕维的合成

以7-羟甲基-1-四氢萘酮和1-溴-4-氯-苯甲醛为起始原料,经14步反应合成了抗丙肝新药维拉帕维--甲基（2S）-1-【(2S,5S)-2-【9{2［（2S,4S）-1-（2R)-2-［（甲氧基羰基）氨基］-2-苯乙酰基-4-（甲氧基甲基）吡咯烷-2-基］-1H-咪唑 5 基} 1,11-二氢异色烯［4′,3′ :6,7］萘并［1,2-d］咪唑-2-基-5-甲基吡咯烷-1-基】-3-甲基-1-氧丁烷-2-基】氨基甲酸酯,总产率10.14%,其结构经¹H NMR和ESI-MS确证。     

三乙烯二胺催化Michael加成对(E)-β-芳(烷)氧基丙烯酸酯的立体选择性合成

以异丙醇为溶剂(或无溶剂),采用三乙烯二胺(DABCO)催化的取代苯酚(或取代苄醇)与2-丁炔酸乙酯的Michael加成反应合成了14个(E)-β-芳氧基丙烯酸酯化合物(3a~3n,3f~3n为新化合物)和3个烷氧基丙烯酸酯化合物(5a,5b和5k,5b和5k为新化合物),收率分别为85%~99%和60%~68%,其结构经1H NMR,13C NMR和HR-MS(ESI)表征。以3a的合成为例,优化了合成3的反应条件。结果表明:在最优反应条件(DABCO为催化剂,异丙醇为溶剂,于25℃反应9 h)下,3a收率92%,E∶Z99∶1。     

新型芳姜黄酮拼合吡咯螺环氧化吲哚类化合物的合成及其抗肿瘤活性

以取代靛红和肌氨酸为原料制得1,3-偶极子,再与(E)-芳姜烯酮类化合物在乙腈中经3+2环加成反应合成了10个新型的芳姜黄酮拼合吡咯螺环氧化吲哚类化合物(3a~3j)产率70%~91%, d/r值15 :1~>20:1,其结构经¹H NMR, ¹³C NMR和HR-MS（ESI-TOF）表征。采用MTT法研究了3a~3j对人肺癌细胞(A549)和人白血病细胞(K562)的体外抗肿瘤活性。结果表明：3f对K562抑制活性较好（IC₅₀=31.1 μmol·L^-1）, 3b对A549抑制活性较好（IC₅₀=54.1 μmol·L^-1）。     

Syntheses and characterization of new (2S)-2-hydroxy-1,4-oxazin-3-ones derived from β-aminoalcohols

The reactions of methyl glyoxylate hemiacetal 1 with 2-(methylamino)ethanol 2 , (1R,2S)-(–)-ephedrine 3 and (1S,2S)-(+)-pseudoephedrine 4 provide the (2S)-2-hydroxy-1,4-oxazin-3-ones 2a , 3a , 4a in good yield. They were characterized by ¹H, ¹³C, NMR, and infrared and mass spectroscopy. The structures of 2a and 3a were established by X-ray diffraction. The configuration of C₂ (S) is demonstrated by ¹H NMR data and confirmed for compounds 2a and 3a by single-crystal X-ray diffraction studies. © John Wiley & Sons, Inc.